Ibm-moderna-partner

Blockchain is coming to rescue COVID-19 supply chain

Last Updated: March 9, 2021By

Moderna and IBM have planned to explore how to distribute the COVID-19 vaccine using Blockchain, AI, and other technologies.

The pharmaceutical company is organizing a blockchain pilot to provide vaccines throughout. The government and healthcare providers are facing issues in supplying the COVID-19 vaccines from the manufacturer to the destination.

One of IBM’s in-house blockchain offerings is IBM Food Trust that provides similar results but in different sectors. Previously, IBM participated in an FDA pharmaceutical project and launched a Blockchain unit known as the Pharmaceutical Utility Network (PhUN).

Another famous amalgamation took place between Moderna and IBM, for Digital Health Pass. Digital Health Pass is a solution that allows blockchain to enable vaccine or test credentials to be verified. It recently uncovered a project with New York state, including the events at Madison Square Garden.

Michael Mullet, MD of Moderna, said that they are looking forward to applying digital innovations between organizations and governments.

Besides, IBM has started to offer wider solutions beyond health certificates. Moderna is a huge example here.

Stay informed with daily updates from Blockchain Magazine on Google News. Click here to follow us and mark as favorite: [Blockchain Magazine on Google News].

Gif;base64,r0lgodlhaqabaaaaach5baekaaealaaaaaabaaeaaaictaeaow==

Get Blockchain Insights In Inbox

Stay ahead of the curve with expert analysis and market updates.

Disclaimer: Any post shared by a third-party agency are sponsored and Blockchain Magazine has no views on any such posts. The views and opinions expressed in this post are those of the clients and do not necessarily reflect the official policy or position of Blockchain Magazine. The information provided in this post is for informational purposes only and should not be considered as financial, investment, or professional advice. Blockchain Magazine does not endorse or promote any specific products, services, or companies mentioned in this posts. Readers are encouraged to conduct their own research and consult with a qualified professional before making any financial decisions.

About the Author: Editor's Desk

Avatar